5.38 - 5.60
4.95 - 8.28
2.3K / 2.4K (Avg.)
-279.00 | -0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
12.58%
Revenue growth similar to STERV.HE's 13.88%. Walter Schloss would see if both companies share industry tailwinds.
-2.59%
Negative gross profit growth while STERV.HE is at 16.46%. Joel Greenblatt would examine cost competitiveness or demand decline.
26.46%
EBIT growth above 1.5x STERV.HE's 13.04%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
26.46%
Operating income growth above 1.5x STERV.HE's 13.04%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
29.09%
Net income growth at 50-75% of STERV.HE's 43.06%. Martin Whitman would question fundamental disadvantages in expenses or demand.
-25.81%
Negative EPS growth while STERV.HE is at 44.44%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-25.81%
Negative diluted EPS growth while STERV.HE is at 44.44%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.69%
Share reduction while STERV.HE is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.69%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
697.62%
OCF growth above 1.5x STERV.HE's 179.55%. David Dodd would confirm a clear edge in underlying cash generation.
524.12%
FCF growth similar to STERV.HE's 511.67%. Walter Schloss would attribute it to parallel capital spending and operational models.
-17.22%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
43.94%
5Y revenue/share CAGR above 1.5x STERV.HE's 2.61%. David Dodd would look for consistent product or market expansions fueling outperformance.
5.72%
Positive 3Y CAGR while STERV.HE is negative. John Neff might view this as a sharp short-term edge or successful pivot strategy.
674.87%
10Y OCF/share CAGR above 1.5x STERV.HE's 146.38%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
761.09%
Positive OCF/share growth while STERV.HE is negative. John Neff might see a comparative advantage in operational cash viability.
264.22%
3Y OCF/share CAGR above 1.5x STERV.HE's 29.47%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
235.29%
Net income/share CAGR above 1.5x STERV.HE's 53.66% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
283.33%
5Y net income/share CAGR above 1.5x STERV.HE's 64.80%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
91.67%
Positive short-term CAGR while STERV.HE is negative. John Neff would see a clear advantage in near-term profit trajectory.
59.17%
10Y equity/share CAGR 1.25-1.5x STERV.HE's 49.59%. Bruce Berkowitz would see if strong ROE or conservative payout policy fosters faster book value growth.
69.86%
5Y equity/share CAGR is in line with STERV.HE's 67.63%. Walter Schloss would see parallel mid-term profitability and retention policies.
29.41%
3Y equity/share CAGR at 50-75% of STERV.HE's 52.34%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
67.55%
Stable or rising mid-term dividends while STERV.HE is cutting. John Neff sees an edge in consistent payouts vs. the competitor.
22.04%
Our short-term dividend growth is positive while STERV.HE cut theirs. John Neff views it as a comparative advantage in shareholder returns.
8.76%
AR growth well above STERV.HE's 12.68%. Michael Burry fears inflated revenue or higher default risk in the near future.
-5.91%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
2.40%
Asset growth at 75-90% of STERV.HE's 2.85%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
7.30%
1.25-1.5x STERV.HE's 5.73%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
-2.48%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
-8.39%
We cut SG&A while STERV.HE invests at 12.56%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.